狼疮低疾病活动度状态作为系统性红斑狼疮治疗终点的前瞻性验证研究
BACKGROUND: Treat-to-target strategies have improved outcomes in single-organ diseases with simple clinical or laboratory endpoints.…
要点
- LLDAS对减少损伤累积的关联不受基线损伤或疾病活动度影响。
核心结论
- LLDAS达标与SLE患者复发和不可逆器官损伤累积的显著保护作用相关,验证了LLDAS作为SLE临床研究终点的有效性。
主要发现
- 持续LLDAS时间延长与损伤累积风险逐步降低相关。
关键数值与推荐
- LLDAS达标定义为每次访视时评估的狼疮低疾病活动度状态。
- 主要结局为SLICC/ACR损伤指数较基线增加至少1分。
临床怎么用
- 在SLE临床实践中可将LLDAS作为治疗目标,以降低复发和器官损伤累积风险。
- 应关注LLDAS的累积达标时间,维持≥50%观察时间处于LLDAS可带来更优结局。
局限性
- 本研究为观察性队列,LLDAS与结局的关联可能受未测量混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treat-to-target strategies have improved outcomes in single-organ diseases with simple clinical or laboratory endpoints. A lack of validated endpoints has prevented adoption of treat to target for complex multiorgan conditions, such as systemic lupus erythematosus (SLE). We report the first prospective study undertaken to specifically validate a treat-to-target endpoint for SLE. METHODS: In this prospective cohort study, patients aged 18 years or older with SLE were recruited from 13 centres in eight countries and followed prospectively. Patients with at least two visits over the study period no more than 6 months apart were included in the longitudinal analysis. Patients with no visits in the final year of the study were censored from their last visit. Attainment of the lupus low disease activity state (LLDAS) was assessed at each visit. The primary outcome measure was accrual of irreversible end-organ damage, defined as at least a 1-point increase in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. We used time-dependent hazard regression models and generalised linear models to measure the association between LLDAS (attainment at any timepoint, cumulative time in LLDAS, and sustained LLDAS) with accrual of irreversible end-organ damage or flare (key secondary outcome). This study is registered with ClinicalTrials.gov, NCT03138941. FINDINGS: Between May 1, 2013, and Dec 31, 2016, 1707 patients were recruited and followed for a mean of 2·2 years (SD 0·9), totalling 12 689 visits. Attainment of LLDAS at any timepoint was associated with reduction in damage accrual (hazard ratio 0·59, 0·45-0·76; p<0·0001) and subsequent flare (0·65, 95% CI 0·56-0·75; p<0·0001). Cumulative time in LLDAS was associated with improved outcomes: compared with patients with less than 50% of observed time in LLDAS, those with at least 50% of observed time in LLDAS had reduced risk of damage accrual (0·54, 0·42-0·70; p<0·0001) and flare (0·41, 0·35-0·48; p<0·0001). Similarly, increased durations of sustained LLDAS were associated with incremental reductions in the risk of damage accrual. The association of LLDAS with reduced damage accrual was observed regardless of pre-existing damage or disease activity at study entry. INTERPRETATION: LLDAS attainment is associated with significant protection against flare and damage accrual in SLE. These findings validate LLDAS as an endpoint for clinical studies in SLE. FUNDING: The Asia Pacific Lupus Collaboration received project support grants from UCB Pharma, GlaxoSmithKline, Janssen, Bristol-Myers Squibb, and AstraZeneca.
引用
- Golder V, Kandane-Rathnayake R, Huq M, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatol. 2019. PMID: 38229349. doi:10.1016/S2665-9913(19)30037-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。